Compare Novo Nordisk A/S (NVO) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Visa Inc — how do they compare? Novo Nordisk A/S trades at $44.75 (market cap $200.69B), while Visa Inc trades at $369.32 (market cap $693.57B). The key difference: Visa Inc is far larger — about 3.5× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | V | |
|---|---|---|
Market Cap | $200.69B | $693.57B |
Sector | Health | Financials |
52-Week High | $63.98 | $384.14 |
52-Week Low | $35.29 | $295.52 |
Enterprise Value | $215.49B | $704.15B |
Dividend Yield | 3.98% | 0.73% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Visa (V) trades at $368.64, down 1.71% on the day, amid a bullish technical setup with strong support at $366 and resistance at $372. The company reported robust fundamentals with Q2 2026 earnings beating estimates, revenue growth to $40B in 2025, and a net income margin of 50.78%. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships, signaling innovation in payments.
Outlook remains positive with an analyst consensus price target of $430.93 (17% upside), supported by high profitability and strategic initiatives. Risks include fintech competition and regulatory pressures, but institutional ownership trends and a debt-to-asset ratio of 25.26% reflect financial stability. The stock presents a long-term growth opportunity with manageable headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
